Genetic profiling of MYCand BCL2in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact

MLA

Ennishi, Daisuke, et al. “Genetic Profiling of MYCand BCL2in Diffuse Large B-Cell Lymphoma Determines Cell-of-Origin–specific Clinical Impact.” Blood, vol. 129, no. 20, May 2017, pp. 2760–70. EBSCOhost, https://doi.org/10.1182/blood-2016-11-747022.

APA

Ennishi, D., Mottok, A., Ben-Neriah, S., Shulha, H. P., Farinha, P., Chan, F. C., Meissner, B., Boyle, M., Hother, C., Kridel, R., Lai, D., Saberi, S., Bashashati, A., Shah, S. P., Morin, R. D., Marra, M. A., Savage, K. J., Sehn, L. H., Steidl, C., … Scott, D. W. (2017). Genetic profiling of MYCand BCL2in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact. Blood, 129(20), 2760–2770. https://doi.org/10.1182/blood-2016-11-747022

Chicago

Ennishi, Daisuke, Anja Mottok, Susana Ben-Neriah, Hennady P. Shulha, Pedro Farinha, Fong Chun Chan, Barbara Meissner, et al. 2017. “Genetic Profiling of MYCand BCL2in Diffuse Large B-Cell Lymphoma Determines Cell-of-Origin–specific Clinical Impact.” Blood 129 (20): 2760–70. doi:10.1182/blood-2016-11-747022.